Effect	O
of	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
on	O
the	O
pharmacokinetics	O
and	O
transplacental	O
transfer	O
of	O
nifedipine	O
in	O
hypertensive	O
pregnant	O
women	I:C0033011
.	O

Effect	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
on	O
the	O
pharmacokinetics	O
and	O
transplacental	O
transfer	O
of	O
nifedipine	B:C0028066
in	O
hypertensive	O
pregnant	O
women	I:C0033011
.	O

Effect	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
on	O
the	O
pharmacokinetics	O
and	O
transplacental	O
transfer	O
of	O
nifedipine	O
in	O
hypertensive	B:C0020538
pregnant	O
women	I:C0033011
.	O

Effect	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
on	O
the	O
pharmacokinetics	O
and	O
transplacental	O
transfer	O
of	O
nifedipine	O
in	O
hypertensive	O
pregnant	B:C0033011
women	I:C0033011
.	O

Diabetes	B:C0011849
mellitus	I:C0011849
can	O
inhibit	O
cytochrome	O
P450	I:C1142644
3A4	I:C1142644
,	O
an	O
enzyme	O
responsible	O
for	O
the	O
metabolism	O
of	O
nifedipine	O
,	O
used	O
for	O
the	O
treatment	O
of	O
hypertension	O
in	O
pregnant	O
women	I:C0033011
.	O

Diabetes	O
mellitus	I:C0011849
can	O
inhibit	O
cytochrome	B:C1142644
P450	I:C1142644
3A4	I:C1142644
,	O
an	O
enzyme	O
responsible	O
for	O
the	O
metabolism	O
of	O
nifedipine	O
,	O
used	O
for	O
the	O
treatment	O
of	O
hypertension	O
in	O
pregnant	O
women	I:C0033011
.	O

Diabetes	O
mellitus	I:C0011849
can	O
inhibit	O
cytochrome	O
P450	I:C1142644
3A4	I:C1142644
,	O
an	O
enzyme	B:C0014442
responsible	O
for	O
the	O
metabolism	O
of	O
nifedipine	O
,	O
used	O
for	O
the	O
treatment	O
of	O
hypertension	O
in	O
pregnant	O
women	I:C0033011
.	O

Diabetes	O
mellitus	I:C0011849
can	O
inhibit	O
cytochrome	O
P450	I:C1142644
3A4	I:C1142644
,	O
an	O
enzyme	O
responsible	O
for	O
the	O
metabolism	B:C0683140
of	O
nifedipine	O
,	O
used	O
for	O
the	O
treatment	O
of	O
hypertension	O
in	O
pregnant	O
women	I:C0033011
.	O

Diabetes	O
mellitus	I:C0011849
can	O
inhibit	O
cytochrome	O
P450	I:C1142644
3A4	I:C1142644
,	O
an	O
enzyme	O
responsible	O
for	O
the	O
metabolism	O
of	O
nifedipine	B:C0028066
,	O
used	O
for	O
the	O
treatment	O
of	O
hypertension	O
in	O
pregnant	O
women	I:C0033011
.	O

Diabetes	O
mellitus	I:C0011849
can	O
inhibit	O
cytochrome	O
P450	I:C1142644
3A4	I:C1142644
,	O
an	O
enzyme	O
responsible	O
for	O
the	O
metabolism	O
of	O
nifedipine	O
,	O
used	O
for	O
the	O
treatment	B:C0087111
of	O
hypertension	O
in	O
pregnant	O
women	I:C0033011
.	O

Diabetes	O
mellitus	I:C0011849
can	O
inhibit	O
cytochrome	O
P450	I:C1142644
3A4	I:C1142644
,	O
an	O
enzyme	O
responsible	O
for	O
the	O
metabolism	O
of	O
nifedipine	O
,	O
used	O
for	O
the	O
treatment	O
of	O
hypertension	B:C0020538
in	O
pregnant	O
women	I:C0033011
.	O

Diabetes	O
mellitus	I:C0011849
can	O
inhibit	O
cytochrome	O
P450	I:C1142644
3A4	I:C1142644
,	O
an	O
enzyme	O
responsible	O
for	O
the	O
metabolism	O
of	O
nifedipine	O
,	O
used	O
for	O
the	O
treatment	O
of	O
hypertension	O
in	O
pregnant	B:C0033011
women	I:C0033011
.	O

We	O
aimed	O
to	O
assess	O
the	O
effect	O
of	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
(	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
)	O
on	O
the	O
pharmacokinetics	O
,	O
placental	O
transfer	O
and	O
distribution	O
of	O
nifedipine	O
in	O
amniotic	O
fluid	I:C0002638
in	O
hypertensive	O
pregnant	O
women	I:C0033011
.	O

We	O
aimed	O
to	O
assess	O
the	O
effect	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
(	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
)	O
on	O
the	O
pharmacokinetics	O
,	O
placental	O
transfer	O
and	O
distribution	O
of	O
nifedipine	O
in	O
amniotic	O
fluid	I:C0002638
in	O
hypertensive	O
pregnant	O
women	I:C0033011
.	O

We	O
aimed	O
to	O
assess	O
the	O
effect	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
(	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
)	O
on	O
the	O
pharmacokinetics	O
,	O
placental	O
transfer	O
and	O
distribution	O
of	O
nifedipine	B:C0028066
in	O
amniotic	O
fluid	I:C0002638
in	O
hypertensive	O
pregnant	O
women	I:C0033011
.	O

We	O
aimed	O
to	O
assess	O
the	O
effect	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
(	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
)	O
on	O
the	O
pharmacokinetics	O
,	O
placental	O
transfer	O
and	O
distribution	O
of	O
nifedipine	O
in	O
amniotic	B:C0002638
fluid	I:C0002638
in	O
hypertensive	O
pregnant	O
women	I:C0033011
.	O

We	O
aimed	O
to	O
assess	O
the	O
effect	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
(	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
)	O
on	O
the	O
pharmacokinetics	O
,	O
placental	O
transfer	O
and	O
distribution	O
of	O
nifedipine	O
in	O
amniotic	O
fluid	I:C0002638
in	O
hypertensive	B:C0020538
pregnant	O
women	I:C0033011
.	O

We	O
aimed	O
to	O
assess	O
the	O
effect	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
(	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
)	O
on	O
the	O
pharmacokinetics	O
,	O
placental	O
transfer	O
and	O
distribution	O
of	O
nifedipine	O
in	O
amniotic	O
fluid	I:C0002638
in	O
hypertensive	O
pregnant	B:C0033011
women	I:C0033011
.	O

The	O
study	B:C2603343
was	O
conducted	O
in	O
12	O
hypertensive	O
pregnant	O
women	I:C0033011
[	O
control	O
group	O
(	O
CG	O
)	O
]	O
and	O
10	O
hypertensive	O
pregnant	O
women	I:C0033011
with	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
taking	O
slow	O
-	O
release	O
nifedipine	O
(	O
20	O
mg	O
,	O
12/12	O
h	O
)	O
.	O

The	O
study	O
was	O
conducted	O
in	O
12	O
hypertensive	B:C0020538
pregnant	O
women	I:C0033011
[	O
control	O
group	O
(	O
CG	O
)	O
]	O
and	O
10	O
hypertensive	O
pregnant	O
women	I:C0033011
with	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
taking	O
slow	O
-	O
release	O
nifedipine	O
(	O
20	O
mg	O
,	O
12/12	O
h	O
)	O
.	O

The	O
study	O
was	O
conducted	O
in	O
12	O
hypertensive	O
pregnant	B:C0033011
women	I:C0033011
[	O
control	O
group	O
(	O
CG	O
)	O
]	O
and	O
10	O
hypertensive	O
pregnant	O
women	I:C0033011
with	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
taking	O
slow	O
-	O
release	O
nifedipine	O
(	O
20	O
mg	O
,	O
12/12	O
h	O
)	O
.	O

The	O
study	O
was	O
conducted	O
in	O
12	O
hypertensive	O
pregnant	O
women	I:C0033011
[	O
control	O
group	O
(	O
CG	O
)	O
]	O
and	O
10	O
hypertensive	B:C0020538
pregnant	O
women	I:C0033011
with	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
taking	O
slow	O
-	O
release	O
nifedipine	O
(	O
20	O
mg	O
,	O
12/12	O
h	O
)	O
.	O

The	O
study	O
was	O
conducted	O
in	O
12	O
hypertensive	O
pregnant	O
women	I:C0033011
[	O
control	O
group	O
(	O
CG	O
)	O
]	O
and	O
10	O
hypertensive	O
pregnant	B:C0033011
women	I:C0033011
with	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
taking	O
slow	O
-	O
release	O
nifedipine	O
(	O
20	O
mg	O
,	O
12/12	O
h	O
)	O
.	O

The	O
study	O
was	O
conducted	O
in	O
12	O
hypertensive	O
pregnant	O
women	I:C0033011
[	O
control	O
group	O
(	O
CG	O
)	O
]	O
and	O
10	O
hypertensive	O
pregnant	O
women	I:C0033011
with	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
taking	O
slow	O
-	O
release	O
nifedipine	O
(	O
20	O
mg	O
,	O
12/12	O
h	O
)	O
.	O

The	O
study	O
was	O
conducted	O
in	O
12	O
hypertensive	O
pregnant	O
women	I:C0033011
[	O
control	O
group	O
(	O
CG	O
)	O
]	O
and	O
10	O
hypertensive	O
pregnant	O
women	I:C0033011
with	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
taking	O
slow	O
-	O
release	O
nifedipine	B:C0028066
(	O
20	O
mg	O
,	O
12/12	O
h	O
)	O
.	O

On	O
the	O
34th	O
week	O
of	O
gestation	B:C0032961
,	O
serial	O
blood	O
samples	I:C0178913
were	O
collected	O
(	O
0	O
-	O
12	O
h	O
)	O
after	O
administration	O
of	O
the	O
medication	O
.	O

On	O
the	O
34th	O
week	O
of	O
gestation	O
,	O
serial	O
blood	B:C0178913
samples	I:C0178913
were	O
collected	O
(	O
0	O
-	O
12	O
h	O
)	O
after	O
administration	O
of	O
the	O
medication	O
.	O

On	O
the	O
34th	O
week	O
of	O
gestation	O
,	O
serial	O
blood	O
samples	I:C0178913
were	O
collected	O
(	O
0	O
-	O
12	O
h	O
)	O
after	O
administration	B:C1533734
of	O
the	O
medication	O
.	O

On	O
the	O
34th	O
week	O
of	O
gestation	O
,	O
serial	O
blood	O
samples	I:C0178913
were	O
collected	O
(	O
0	O
-	O
12	O
h	O
)	O
after	O
administration	O
of	O
the	O
medication	B:C0013227
.	O

At	O
delivery	O
,	O
samples	B:C0178913
of	O
maternal	O
and	O
fetal	O
blood	I:C0015925
and	O
amniotic	O
fluid	I:C0002638
were	O
collected	O
for	O
determination	O
of	O
nifedipine	O
distribution	O
in	O
these	O
compartments	O
.	O

At	O
delivery	O
,	O
samples	O
of	O
maternal	O
and	O
fetal	B:C0015925
blood	I:C0015925
and	O
amniotic	O
fluid	I:C0002638
were	O
collected	O
for	O
determination	O
of	O
nifedipine	O
distribution	O
in	O
these	O
compartments	O
.	O

At	O
delivery	O
,	O
samples	O
of	O
maternal	O
and	O
fetal	O
blood	I:C0015925
and	O
amniotic	B:C0002638
fluid	I:C0002638
were	O
collected	O
for	O
determination	O
of	O
nifedipine	O
distribution	O
in	O
these	O
compartments	O
.	O

At	O
delivery	O
,	O
samples	O
of	O
maternal	O
and	O
fetal	O
blood	I:C0015925
and	O
amniotic	O
fluid	I:C0002638
were	O
collected	O
for	O
determination	B:C1148554
of	O
nifedipine	O
distribution	O
in	O
these	O
compartments	O
.	O

At	O
delivery	O
,	O
samples	O
of	O
maternal	O
and	O
fetal	O
blood	I:C0015925
and	O
amniotic	O
fluid	I:C0002638
were	O
collected	O
for	O
determination	O
of	O
nifedipine	B:C0028066
distribution	O
in	O
these	O
compartments	O
.	O

The	O
parameters	O
for	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
group	O
were	O
:	O
Cmax	O
23.52	O
ng	O
ml	O
(	O
-	O
1	O
)	O
,	O
tmax	O
1.48	O
h	O
,	O
AUC	O
0	O
-	O
12	O
202.23	O
ng.h	O
ml	O
(	O
-	O
1	O
)	O
,	O
tÂ½	O
5.00	O
h	O
,	O
Vd	O
/	O
F	O
609.40	O
l	O
,	O
and	O
apparent	O
total	O
clearance	O
(	O
ClT	O
/	O
F	O
)	O
98.94	O
l	O
h	O
(	O
-	O
1	O
)	O
.	O

The	O
parameters	O
for	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
group	B:C1257890
were	O
:	O
Cmax	O
23.52	O
ng	O
ml	O
(	O
-	O
1	O
)	O
,	O
tmax	O
1.48	O
h	O
,	O
AUC	O
0	O
-	O
12	O
202.23	O
ng.h	O
ml	O
(	O
-	O
1	O
)	O
,	O
tÂ½	O
5.00	O
h	O
,	O
Vd	O
/	O
F	O
609.40	O
l	O
,	O
and	O
apparent	O
total	O
clearance	O
(	O
ClT	O
/	O
F	O
)	O
98.94	O
l	O
h	O
(	O
-	O
1	O
)	O
.	O

The	O
ratios	O
of	O
plasma	O
concentrations	O
of	O
nifedipine	B:C0028066
in	O
the	O
umbilical	O
vein	I:C0041637
,	O
intervillous	O
space	I:C0230968
and	O
amniotic	O
fluid	I:C0002638
to	O
those	O
in	O
the	O
maternal	O
vein	O
for	O
CG	O
and	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
were	O
0.53	O
and	O
0.44	O
,	O
0.78	O
and	O
0.87	O
,	O
respectively	O
,	O
with	O
an	O
amniotic	O
fluid	I:C0002638
/	O
maternal	O
plasma	O
ratio	O
of	O
0.05	O
for	O
both	O
groups	O
.	O

The	O
ratios	O
of	O
plasma	O
concentrations	O
of	O
nifedipine	O
in	O
the	O
umbilical	B:C0041637
vein	I:C0041637
,	O
intervillous	O
space	I:C0230968
and	O
amniotic	O
fluid	I:C0002638
to	O
those	O
in	O
the	O
maternal	O
vein	O
for	O
CG	O
and	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
were	O
0.53	O
and	O
0.44	O
,	O
0.78	O
and	O
0.87	O
,	O
respectively	O
,	O
with	O
an	O
amniotic	O
fluid	I:C0002638
/	O
maternal	O
plasma	O
ratio	O
of	O
0.05	O
for	O
both	O
groups	O
.	O

The	O
ratios	O
of	O
plasma	O
concentrations	O
of	O
nifedipine	O
in	O
the	O
umbilical	O
vein	I:C0041637
,	O
intervillous	B:C0230968
space	I:C0230968
and	O
amniotic	O
fluid	I:C0002638
to	O
those	O
in	O
the	O
maternal	O
vein	O
for	O
CG	O
and	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
were	O
0.53	O
and	O
0.44	O
,	O
0.78	O
and	O
0.87	O
,	O
respectively	O
,	O
with	O
an	O
amniotic	O
fluid	I:C0002638
/	O
maternal	O
plasma	O
ratio	O
of	O
0.05	O
for	O
both	O
groups	O
.	O

The	O
ratios	O
of	O
plasma	O
concentrations	O
of	O
nifedipine	O
in	O
the	O
umbilical	O
vein	I:C0041637
,	O
intervillous	O
space	I:C0230968
and	O
amniotic	B:C0002638
fluid	I:C0002638
to	O
those	O
in	O
the	O
maternal	O
vein	O
for	O
CG	O
and	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
were	O
0.53	O
and	O
0.44	O
,	O
0.78	O
and	O
0.87	O
,	O
respectively	O
,	O
with	O
an	O
amniotic	O
fluid	I:C0002638
/	O
maternal	O
plasma	O
ratio	O
of	O
0.05	O
for	O
both	O
groups	O
.	O

The	O
ratios	O
of	O
plasma	O
concentrations	O
of	O
nifedipine	O
in	O
the	O
umbilical	O
vein	I:C0041637
,	O
intervillous	O
space	I:C0230968
and	O
amniotic	O
fluid	I:C0002638
to	O
those	O
in	O
the	O
maternal	O
vein	O
for	O
CG	O
and	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
were	O
0.53	O
and	O
0.44	O
,	O
0.78	O
and	O
0.87	O
,	O
respectively	O
,	O
with	O
an	O
amniotic	O
fluid	I:C0002638
/	O
maternal	O
plasma	O
ratio	O
of	O
0.05	O
for	O
both	O
groups	O
.	O

The	O
ratios	O
of	O
plasma	O
concentrations	O
of	O
nifedipine	O
in	O
the	O
umbilical	O
vein	I:C0041637
,	O
intervillous	O
space	I:C0230968
and	O
amniotic	O
fluid	I:C0002638
to	O
those	O
in	O
the	O
maternal	O
vein	O
for	O
CG	O
and	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
were	O
0.53	O
and	O
0.44	O
,	O
0.78	O
and	O
0.87	O
,	O
respectively	O
,	O
with	O
an	O
amniotic	B:C0002638
fluid	I:C0002638
/	O
maternal	O
plasma	O
ratio	O
of	O
0.05	O
for	O
both	O
groups	O
.	O

The	O
ratios	O
of	O
plasma	O
concentrations	O
of	O
nifedipine	O
in	O
the	O
umbilical	O
vein	I:C0041637
,	O
intervillous	O
space	I:C0230968
and	O
amniotic	O
fluid	I:C0002638
to	O
those	O
in	O
the	O
maternal	O
vein	O
for	O
CG	O
and	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
were	O
0.53	O
and	O
0.44	O
,	O
0.78	O
and	O
0.87	O
,	O
respectively	O
,	O
with	O
an	O
amniotic	O
fluid	I:C0002638
/	O
maternal	O
plasma	B:C0032105
ratio	O
of	O
0.05	O
for	O
both	O
groups	O
.	O

The	O
ratios	O
of	O
plasma	O
concentrations	O
of	O
nifedipine	O
in	O
the	O
umbilical	O
vein	I:C0041637
,	O
intervillous	O
space	I:C0230968
and	O
amniotic	O
fluid	I:C0002638
to	O
those	O
in	O
the	O
maternal	O
vein	O
for	O
CG	O
and	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
were	O
0.53	O
and	O
0.44	O
,	O
0.78	O
and	O
0.87	O
,	O
respectively	O
,	O
with	O
an	O
amniotic	O
fluid	I:C0002638
/	O
maternal	O
plasma	O
ratio	O
of	O
0.05	O
for	O
both	O
groups	B:C1257890
.	O

The	O
ratios	O
of	O
plasma	O
concentrations	O
in	O
the	O
umbilical	B:C0041632
artery	I:C0041632
to	O
those	O
in	O
the	O
umbilical	O
vein	I:C0041637
were	O
0.82	O
for	O
CG	O
and	O
0.88	O
for	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
.	O

The	O
ratios	O
of	O
plasma	O
concentrations	O
in	O
the	O
umbilical	O
artery	I:C0041632
to	O
those	O
in	O
the	O
umbilical	B:C0041637
vein	I:C0041637
were	O
0.82	O
for	O
CG	O
and	O
0.88	O
for	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
.	O

The	O
ratios	O
of	O
plasma	O
concentrations	O
in	O
the	O
umbilical	O
artery	I:C0041632
to	O
those	O
in	O
the	O
umbilical	O
vein	I:C0041637
were	O
0.82	O
for	O
CG	O
and	O
0.88	O
for	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
.	O

There	O
was	O
no	O
influence	O
of	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
on	O
the	O
pharmacokinetics	O
or	O
placental	O
transfer	O
of	O
nifedipine	O
in	O
hypertensive	O
women	O
with	O
controlled	O
diabetes	O
.	O

There	O
was	O
no	O
influence	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
on	O
the	O
pharmacokinetics	O
or	O
placental	O
transfer	O
of	O
nifedipine	B:C0028066
in	O
hypertensive	O
women	O
with	O
controlled	O
diabetes	O
.	O

There	O
was	O
no	O
influence	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
on	O
the	O
pharmacokinetics	O
or	O
placental	O
transfer	O
of	O
nifedipine	O
in	O
hypertensive	B:C0020538
women	O
with	O
controlled	O
diabetes	O
.	O

There	O
was	O
no	O
influence	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
on	O
the	O
pharmacokinetics	O
or	O
placental	O
transfer	O
of	O
nifedipine	O
in	O
hypertensive	O
women	B:C0043210
with	O
controlled	O
diabetes	O
.	O

There	O
was	O
no	O
influence	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
on	O
the	O
pharmacokinetics	O
or	O
placental	O
transfer	O
of	O
nifedipine	O
in	O
hypertensive	O
women	O
with	O
controlled	B:C2911690
diabetes	O
.	O

There	O
was	O
no	O
influence	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
on	O
the	O
pharmacokinetics	O
or	O
placental	O
transfer	O
of	O
nifedipine	O
in	O
hypertensive	O
women	O
with	O
controlled	O
diabetes	B:C0011847
.	O

